Mirion Technologies Awarded Contracts for TerraPower Natrium® Reactor Demonstration Project

Mirion selected to supply Radiation Monitoring System (RMS) and Nuclear Instrumentation System (XIS) for advanced nuclear reactor project.

ATLANTA--(BUSINESS WIRE)-- Mirion (NYSE: MIR), a global leader in radiation safety, science, and medicine, has been selected to supply the Radiation Monitoring System (RMS) and Nuclear Instrumentation System (XIS) to support the Natrium Reactor Demonstration Project in Wyoming. This project marks the first commercial advanced nuclear power plant in the U.S. and is a public-private partnership between TerraPower, a leading nuclear innovation company, and the U.S. Department of Energy (DOE). The goal is to deploy the Natrium technology, which combines a sodium-cooled fast reactor with a molten salt energy storage system.

The contracts recently awarded by TerraPower are for two key systems. Mirion RMS solutions – comprised of area, effluent, and process radiation monitors – will continuously monitor plant radiation levels, enhancing safety and supporting operational efficiency. Through the XIS contract, Mirion will deliver critical instrumentation for detecting reactor power levels, supporting the plant’s advanced capabilities.

These contracts will allow Mirion the continued opportunity to deliver on its commitment to support innovative nuclear technologies, such as small and advanced modular reactors, and meet modern energy demands with safe, sustainable nuclear power.

“Our team is honored to be a part of the exciting and essential project in Wyoming,” said Mirion CEO Thomas Logan. “TerraPower’s Natrium project represents significant potential for faster, lower-cost paths to addressing increasing energy demands, and Mirion solutions will play a crucial role in ensuring the safety and operational efficiency of this pioneering work.”

“We look forward to collaborating with TerraPower, the DOE, and all groups involved to ensure success in Wyoming and beyond,” added Logan.

About Mirion

Mirion (NYSE: MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. Focused on nuclear and safety, the Mirion Technologies group is committed to powering advancements in nuclear energy through proven radiation safety technologies and expertise. Dedicated to driving better patient outcomes, the Mirion Medical group is focused on improving quality in cancer care through its broad range of solutions that enhance the delivery and ensure safety across the medical landscape. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,800 people and operates in 12 countries. Learn more at https://www.mirion.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250331207132/en/

For investor inquiries:

Eric Linn

ir@mirion.com

For media inquiries:

Erin Schesny

media@mirion.com

Source: Mirion